EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS BEYOND PROGRESSIVE DISEASE: A RETROSPECTIVE ANALYSIS FOR JAPANESE PATIENTS WITH ACTIVATING EGFR MUTATIONS

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

It is not determined whether the continuous use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) is reasonable for patients with activating EGFR mutations who have progressed with the drug.

Methods

We retrospectively analyzed the data from 2002 to 2010 of consecutive patients who had advanced non-small-cell lung cancer (NSCLC) harboring activating EGFR mutations, and showed radiological disease progression after EGFR-TKI treatment as the first-line or second-line setting. We classified them into two groups: continuous EGFR-TKI and switching to chemotherapy, and comparedthe clinical outcome. Multivariate analysis for survival was carried out including age, gender, ECOG performance status (PS: 0-1/ 2-4), brain metastasis, EGFR mutations (deletions in exon 19 versus L858R), continuous EGFR-TKI (yes/no), initiation of EGFR-TKI (1st versus 2nd).

Results

A total of 551 NSCLC patients were screened for EGFR mutations in the period, and 210 patients had EGFR mutations. To explore the use of EGFR-TKI beyond progressive disease (PD), 46 patients were selected and analyzed. There were 9 males and 37 females, and median age was 65 years (42–86 years). Among them, 23 patients had deletions in exon 19, and 23 had a point mutation of L858R in exon 21. Twenty-five patients were continuing EGFR-TKI beyond PD. Twenty-one patients were switched to cytotoxic chemotherapy alone. The median overall survival (OS) was 60.8 months in the patients continuing EGFR-TKI, and 23.9 months in the patients receiving chemotherapy, presenting a significant difference between the two groups (P = 0.0081). Cox analysis showed that continuous EGFR-TKI after PD (HR 0.28, 95% CI: 0.10–0.76, P = 0.01) was associated with improved survival.

Conclusion

Continuous use of EGFR-TKI beyond PD may prolong OS compared with switching to cytotoxic chemotherapy in patients with activating EGFR mutations. A prospective study will be needed to confirm our results.

Related Topics

    loading  Loading Related Articles